- Home
- TARA vs CSBR Comparison
TARA vs CSBR Comparison
Compare TARA & CSBR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TARA
- CSBR
- Stock Information
- Founded
- TARA N/A
- CSBR 1985
- Country
- TARA United States
- CSBR United States
- Employees
- TARA N/A
- CSBR N/A
- Industry
- TARA Biotechnology: Biological Products (No Diagnostic Substances)
- CSBR Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TARA Health Care
- CSBR Health Care
- Exchange
- TARA Nasdaq
- CSBR Nasdaq
- Market Cap
- TARA 118.1M
- CSBR 123.2M
- IPO Year
- TARA N/A
- CSBR 1986
- Fundamental
- Price
- TARA $3.03
- CSBR $6.35
- Analyst Decision
- TARA Strong Buy
- CSBR Strong Buy
- Analyst Count
- TARA 6
- CSBR 1
- Target Price
- TARA $19.80
- CSBR $12.00
- AVG Volume (30 Days)
- TARA 148.6K
- CSBR 36.4K
- Earning Date
- TARA 11-11-2025
- CSBR 09-15-2025
- Dividend Yield
- TARA N/A
- CSBR N/A
- EPS Growth
- TARA N/A
- CSBR N/A
- EPS
- TARA N/A
- CSBR 0.21
- Revenue
- TARA N/A
- CSBR $56,878,000.00
- Revenue This Year
- TARA N/A
- CSBR $9.30
- Revenue Next Year
- TARA N/A
- CSBR $31.17
- P/E Ratio
- TARA N/A
- CSBR $30.21
- Revenue Growth
- TARA N/A
- CSBR 10.11
- 52 Week Low
- TARA $1.60
- CSBR $3.75
- 52 Week High
- TARA $10.48
- CSBR $11.99
- Technical
- Relative Strength Index (RSI)
- TARA 43.85
- CSBR 44.44
- Support Level
- TARA $3.05
- CSBR $6.33
- Resistance Level
- TARA $3.20
- CSBR $8.74
- Average True Range (ATR)
- TARA 0.13
- CSBR 0.47
- MACD
- TARA -0.01
- CSBR 0.01
- Stochastic Oscillator
- TARA 3.33
- CSBR 1.24
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is committed to identifying and advancing transformative therapies for people with cancer and rare diseases. The company discovers, develops and delivers breakthrough therapies to people who have limited treatment options. Its portfolio includes its program, TARA-002, being developed for the treatment of lymphatic malformations, and intravenous (IV) choline chloride, a phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease (IFALD).
About CSBR Champions Oncology Inc.
Champions Oncology Inc is a USA based company which is engaged in the development and sale of state of the art technology solutions and products to personalize the development and use of oncology drugs. The company operates through one segment namely Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). Its POS business assists physicians in developing personalized treatment options for their cancer patients through tumor-specific data obtained from drug panels and related personalized oncology services. The TOS business assists pharmaceutical and biotechnology companies with their drug development process and offers studies or license tumors for use in studies. The company's revenue is majorly derived from research services.